TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22612620

Group type: EXPERIMENTAL
Intervention: Lansoprazole (LPZ) intravenous infusion at doses of 15 mg, 30 mg, and 60 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lansoprazole (LPZ) intravenous infusion
Number of subjects: 12
Study: 20299988

Group type: EXPERIMENTAL
Intervention: Clonidine 2 microg ml(‐1)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (without clonidine)
Number of subjects: 128
Study: 17999638

Group type: EXPERIMENTAL
Intervention: Vitamins C+E (1 g/day vitamin C plus 400 IU/day vitamin E)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 16060278

Group type: EXPERIMENTAL
Intervention: Static-dynamic exercise (SDE)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard dynamic exercise (SDE)
Number of subjects: 75
Study: 12194626

Group type: EXPERIMENTAL
Intervention: Home rehabilitation with an average of 4.6 physiotherapist visits
Number of subjects: 81

Group type: COMPARATOR
Intervention: Institutional rehabilitation lasting on average 36.2 days (SD 14.6) with daily physiotherapy
Number of subjects: 81
Study: 10091618

Group type: EXPERIMENTAL
Intervention: Biperiden (5 mg intravenously)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Apomorphine (subcutaneously, previously determined dose)
Number of subjects: 17
Study: 8953073

Group type: EXPERIMENTAL
Intervention: Experimental rhinovirus infection (cases)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Noninfected saline‐challenged young adults (controls)
Number of subjects: 11
Study: 2026847

Group type: EXPERIMENTAL
Intervention: Atropine (20 nmol)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Ipratropium
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Pirenzepine (M1 antagonist)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 4-DAMP (M3 antagonist)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: AFDX-116 (M2 antagonist)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Antihistamines (pretreatment)
Number of subjects: 7
Study: 6410736

Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Renografin‐76 (diatrizoate meglumine and diatrizoate sodium)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both iohexol and Renografin‐76
Number of subjects: 40
Study: 30092143

Group type: EXPERIMENTAL
Intervention: H56:IC31 vaccine (two or three vaccinations at different concentrations)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: H56:IC31 vaccine (three vaccinations)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: H56:IC31 vaccine (various doses)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo (not explicitly mentioned but implied as control)
Number of subjects: 98
Study: 30149332

Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) + CBT, n = 70
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo + CBT
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) + CBT
Number of subjects: 142
Study: 27481884

Group type: EXPERIMENTAL
Intervention: 9 mg of sodium hyaluronate in 3 mL of a 0.9% sodium saline solution
Number of subjects: 116

Group type: COMPARATOR
Intervention: 0.9% sodium chloride saline solution
Number of subjects: 116
Study: 25301251

Group type: EXPERIMENTAL
Intervention: Daily self-weighing intervention with a set of weighing scales
Number of subjects: 183

Group type: COMPARATOR
Intervention: Control group (received two weight loss consultations known to be ineffective)
Number of subjects: 183
Study: 22870245

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise training (AET)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 0
Study: 20959776

Group type: EXPERIMENTAL
Intervention: ALIF+PLF
Number of subjects: 95

Group type: COMPARATOR
Intervention: PLF alone
Number of subjects: 95
Study: 17380472

Group type: EXPERIMENTAL
Intervention: Amniocentesis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mid-trimester amniocentesis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prenatal testing for congenital toxoplasmosis
Number of subjects: 0
Study: 15650632

Group type: EXPERIMENTAL
Intervention: Laparoscopic subtotal gastrectomy (LG)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Open subtotal gastrectomy (OG)
Number of subjects: 59
Study: 12192322

Group type: EXPERIMENTAL
Intervention: Radical pancreaticoduodenectomy (extended)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Standard pancreaticoduodenectomy
Number of subjects: 294
Study: 10439568

Group type: EXPERIMENTAL
Intervention: Hydromorphone
Number of subjects: 74

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 74

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 74
Study: 7557571

Group type: EXPERIMENTAL
Intervention: Coarse bran (15 g)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fine bran (15 g)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no bran)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both bran types
Number of subjects: 12
Study: 2162633

Group type: EXPERIMENTAL
Intervention: ANH group (7.5 ml/kg body weight within 30 min during substitution with 6% HES 200/0.5)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (without hemodilution)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ANH group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 7410734

Group type: EXPERIMENTAL
Intervention: Magnitude estimation ratings of symptom pathology
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Age and sex interaction
Number of subjects: 129

Group type: COMPARATOR
Intervention: Sex alone
Number of subjects: 129
Study: 30336227

Group type: EXPERIMENTAL
Intervention: Nudging with increased saliency of healthiness (not related to calorie content)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anticipated consumption of a healthy meal described as low in caloric content
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anticipated healthy meals not portrayed to be low in calories
Number of subjects: 0
Study: 27458066

Group type: EXPERIMENTAL
Intervention: Shenfu injection (SFI)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (anti-infection, reducing sputum, and support therapy)
Number of subjects: 89
Study: 25467927

Group type: EXPERIMENTAL
Intervention: Oral therapy (lomustine, cyclophosphamide, etoposide)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Intravenous therapy (cyclophosphamide, doxorubicin, vincristine - CAV)
Number of subjects: 131
Study: 23727060

Group type: EXPERIMENTAL
Intervention: Peer support group (20-minute sessions once per week for 12 weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Interpersonal psychotherapy group (1-hour sessions once per week for 12 weeks)
Number of subjects: 44
Study: 21561392

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 19906163

Group type: EXPERIMENTAL
Intervention: ALA-PDT (20% wt/vol aminolevulinic acid hydrochloride)
Number of subjects: 91

Group type: COMPARATOR
Intervention: CO(2) laser
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: ALA-PDT
Number of subjects: 91
Study: 17097185

Group type: EXPERIMENTAL
Intervention: Algorithm 1 (increments of at least 10%, but not exceeding 4U)
Number of subjects: 2442

Group type: COMPARATOR
Intervention: Algorithm 2 (1‐6U increments)
Number of subjects: 2442

Group type: EXPERIMENTAL
Intervention: Algorithm 1
Number of subjects: 2442

Group type: COMPARATOR
Intervention: Algorithm 2
Number of subjects: 2442
Study: 15087974

Group type: EXPERIMENTAL
Intervention: Internal fixation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Casting
Number of subjects: 0
Study: 11586091

Group type: EXPERIMENTAL
Intervention: Pulsed paclitaxel at 15 mg/m2
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Pulsed paclitaxel at 20 mg/m2
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Pulsed paclitaxel at 25 mg/m2
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Pulsed low-dose paclitaxel and radiation
Number of subjects: 23
Study: 10211011

Group type: EXPERIMENTAL
Intervention: 0.3 mg kg‐1 ketoprofen i.v.
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: 1.0 mg kg‐1 ketoprofen i.v.
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: 3.0 mg kg‐1 ketoprofen i.v.
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 7933031

Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasonography
Number of subjects: 67

Group type: COMPARATOR
Intervention: Color Doppler Imaging (CDI)
Number of subjects: 67
Study: 3411660

Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guerin therapy
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Maltose tetrapalmitate
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (transurethral resection only)
Number of subjects: 47
Study: 31820874

Group type: EXPERIMENTAL
Intervention: Orogastric tube guide (GTG)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Conventional 'blind' technique (CONV)
Number of subjects: 151
Study: 30458521

Group type: EXPERIMENTAL
Intervention: Personal Sound Amplification Products (PSAPs)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Hearing Aids
Number of subjects: 25

Group type: COMPARATOR
Intervention: Unaided Listening
Number of subjects: 25
Study: 28088218

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 190

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 190
Study: 26330658

Group type: EXPERIMENTAL
Intervention: High-potassium diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-salt, low-potassium diet
Number of subjects: 0
Study: 24304724

Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Trastuzumab plus Lapatinib
Number of subjects: 100
Study: 21167404

Group type: EXPERIMENTAL
Intervention: Broad-spectrum sunscreen
Number of subjects: 25

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Untreated area
Number of subjects: 25

Group type: COMPARATOR
Intervention: Age of disease onset
Number of subjects: 25
Study: 19061735

Group type: EXPERIMENTAL
Intervention: Intensive cognitive rehabilitation (n=34)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard neurorehabilitation (n=34)
Number of subjects: 68
Study: 17251692

Group type: EXPERIMENTAL
Intervention: High-intensity functional training (FT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Strength training (ST)
Number of subjects: 15
Study: 14988338

Group type: EXPERIMENTAL
Intervention: CPAP (10 cm H(2)O)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bilevel non-invasive ventilation (IPAP 15 cm H(2)O, EPAP 5 cm H(2)O)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional oxygen therapy (Control)
Number of subjects: 60
Study: 11340683

Group type: EXPERIMENTAL
Intervention: Once-daily tobramycin (Mono)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Conventional therapy with tobramycin/ceftazidime (Conv)
Number of subjects: 98
Study: 9448231

Group type: EXPERIMENTAL
Intervention: Nebulized flunisolide nasal spray (250 microg, 1 ml, administered three times daily)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 7960012

Group type: EXPERIMENTAL
Intervention: Ouabain standard or bolus intravenous injections of ouabain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-performance liquid chromatography of sample extracts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enzyme-linked immunosorbent assay for ouabain
Number of subjects: 0
Study: 3109265

Group type: EXPERIMENTAL
Intervention: 35% CO2 challenge
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo treatment (inhalation of air)
Number of subjects: 21
Study: 30258217

Group type: EXPERIMENTAL
Intervention: Combination of two potent bNAbs (3BNC117 and 10-1074) administered at 30 mg kg-1 each
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Combination of two potent bNAbs (3BNC117 and 10-1074)
Number of subjects: 7
Study: 26174907

Group type: EXPERIMENTAL
Intervention: Electronic 7-day diary
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Electronic continuous diary (Cont A)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Electronic partially continuous diary (Cont B)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 3-day paper diary
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 15-week diary schedules
Number of subjects: 100
Study: 24614127

Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine (RV5)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (healthy infants)
Number of subjects: 8
Study: 23214246

Group type: EXPERIMENTAL
Intervention: 153Sm‐EDTMP, injected intravenously at 37.0 MBq/kg body weight
Number of subjects: 55

Group type: COMPARATOR
Intervention: Zoledronic acid, administered by slow intravenous drip at 4 mg in 100 ml of 0.9% sodium chloride
Number of subjects: 55
Study: 20068492

Group type: EXPERIMENTAL
Intervention: Balance training
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Free weights training
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Machine weights training
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Machine weights + balance training
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 18490016

Group type: EXPERIMENTAL
Intervention: Coculture
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (non-coculture)
Number of subjects: 17
Study: 16081477

Group type: EXPERIMENTAL
Intervention: RhEPO (150 IU kg(‐1) weekly subcutaneous injection; n = 8)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (10 ml sterile saline weekly subcutaneous injection; n = 7)
Number of subjects: 15
Study: 12223948

Group type: EXPERIMENTAL
Intervention: Latanoprost monotherapy
Number of subjects: 697

Group type: COMPARATOR
Intervention: Timolol + dorzolamide
Number of subjects: 697
Study: 10689609

Group type: EXPERIMENTAL
Intervention: Intensive case management
Number of subjects: 0
Study: 7760576

Group type: EXPERIMENTAL
Intervention: Coronary angiography recommendation by American physicians
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Availability of cardiac procedures
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Waiting period for cardiac procedures
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Cardiologist proportion
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Interventional cardiologist proportion
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Factors influencing clinical decisions
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Coronary angiography recommendation after adjustment
Number of subjects: 532
Study: 2315645

Group type: EXPERIMENTAL
Intervention: Vitamin E and selenium supplementation (placebo-controlled)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 657058

Group type: EXPERIMENTAL
Intervention: gentamicin-ampicillin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: tobramycin-cephalothin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: amikacin-ampicillin
Number of subjects: 60
Study: 31116883

Group type: EXPERIMENTAL
Intervention: Tai Chi (TC) classes conducted twice/week for 1 year
Number of subjects: 180

Group type: COMPARATOR
Intervention: Health promotion educational classes and social calls (Control)
Number of subjects: 180
Study: 26822516

Group type: EXPERIMENTAL
Intervention: DHA-enriched meals (1720 mg per day for 12 months)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 75
Study: 25462647

Group type: EXPERIMENTAL
Intervention: Alcohol intoxication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High arousal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low arousal
Number of subjects: 0
Study: 23112272

Group type: EXPERIMENTAL
Intervention: Botulinum toxin
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Botulinum toxin B
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Botulinum toxin (doses > 50 U)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Botulinum toxin (doses ≤ 50 U)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study: 20963406

Group type: EXPERIMENTAL
Intervention: DMSO with lignocaine
Number of subjects: 160

Group type: COMPARATOR
Intervention: EMLA cream
Number of subjects: 160
Study: 19761837

Group type: EXPERIMENTAL
Intervention: 30 microg H5N1 influenza vaccine with aluminum hydroxide adjuvant
Number of subjects: 300

Group type: COMPARATOR
Intervention: 7.5 microg H5N1 influenza vaccine without adjuvant
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Both adjuvanted and non-adjuvanted vaccines
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Participants with pre-existing antibodies
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: H5N1 influenza vaccine
Number of subjects: 300
Study: 17535143

Group type: EXPERIMENTAL
Intervention: Treadmill walking with body weight support
Number of subjects: 68

Group type: COMPARATOR
Intervention: Cycling
Number of subjects: 68
Study: 15358996

Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 301

Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 301
Study: 11675833

Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nadroparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 0
Study: 9875717

Group type: EXPERIMENTAL
Intervention: Music score reading
Number of subjects: 8

Group type: COMPARATOR
Intervention: Reading text in primary and secondary language
Number of subjects: 8
Study: 7989932

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (BMT)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Chemotherapy or autologous transplantation (Control)
Number of subjects: 257
Study: 2659151

Group type: EXPERIMENTAL
Intervention: Atenolol 5 mg intravenously followed by 50 mg orally for six days
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 1246976

Group type: EXPERIMENTAL
Intervention: Dietary polyunsaturated fat
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dietary changes in lactating women
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Maternal milk
Number of subjects: 18
Study: 31721260

Group type: EXPERIMENTAL
Intervention: Weighted least squares fitting using calculated pairwise differences (ΔΔG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimal experimental design in pair selection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weighted optimal designs
Number of subjects: 0
Study: 30622224

Group type: EXPERIMENTAL
Intervention: Rapid sequential injection of fentanyl followed by slow injection of hyperbaric bupivacaine
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sequential intrathecal injections of fentanyl and hyperbaric bupivacaine at the same rate
Number of subjects: 56
Study: 29051399

Group type: EXPERIMENTAL
Intervention: Epigastric port-site retrieval (Group B, n=60)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Umbilical port-site retrieval (Group A, n=60)
Number of subjects: 120
Study: 27063132

Group type: EXPERIMENTAL
Intervention: Original occlusion adjustment method
Number of subjects: 20

Group type: COMPARATOR
Intervention: Occlusal plane reduction technique
Number of subjects: 20
Study: 23883922

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg/day
Number of subjects: 222

Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m² every 21 days or 35 mg/m² on days 1, 8, and 15 every 28 days
Number of subjects: 222

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 222
Study: 21255198

Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 19506819

Group type: EXPERIMENTAL
Intervention: Total mesorectal excision (TME)
Number of subjects: 103

Group type: COMPARATOR
Intervention: No total mesorectal excision (Control group)
Number of subjects: 103
Study: 17342993

Group type: EXPERIMENTAL
Intervention: Chinese herbs group (CHG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Western medicated group (WMG)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (WMG and CHG)
Number of subjects: 40
Study: 15151580

Group type: EXPERIMENTAL
Intervention: Partially clothed with only disposable nappies and in posturally supported positions (n = 30)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Naked without postural support (n = 29)
Number of subjects: 59
Study: 11355051

Group type: EXPERIMENTAL
Intervention: Telephone reminders 1 day before appointments
Number of subjects: 903

Group type: COMPARATOR
Intervention: Not telephoned (control group)
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Telephone reminders
Number of subjects: 903
Study: 9014909

Group type: EXPERIMENTAL
Intervention: Killed whole‐cell cholera vaccine (two doses per person)
Number of subjects: 134453

Group type: EXPERIMENTAL
Intervention: Complete two‐dose vaccine regimen
Number of subjects: 134453

Group type: COMPARATOR
Intervention: No vaccine
Number of subjects: 134453
Study: 8200247

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (Lupron Depot 3.75 mg, intramuscularly monthly for three months)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (intramuscularly monthly for three months)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate
Number of subjects: 30
Study: 3115779

Group type: EXPERIMENTAL
Intervention: 20 micrograms min‐1 of GTN
Number of subjects: 7
Study: 30042039

Group type: EXPERIMENTAL
Intervention: N-Butyl Cyanoacrylate (NBCA)
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation (RFA)
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Endovenous Laser Ablation (EVLA)
Number of subjects: 525
Study: 28139587

Group type: EXPERIMENTAL
Intervention: Self-adapting files system (SAF)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Ultrasonic activation of irrigant
Number of subjects: 67

Group type: COMPARATOR
Intervention: Conventional manual tools
Number of subjects: 67